Summary
To determine the efficacy and safety of hepatitis B vaccine (Hevac B) given intradermally, 125 Nigerians (aged 1 year to 45 years), who were negative for hepatitis B virus markers, and randomised into two groups were vaccinated. Group 1 (64 volunteers) was given 3 monthly doses of 2 µg vaccine mixed with adjuvant subcutaneously (Institut Pasteur Production-Hevac B) while group 2 (61 volunteers) received 3 doses of 2 µg non-adjuvated vaccine intradermally given 1 month apart. A month after the third dose 83 per cent of group 1, 71 per cent of group 2 showed positive response by developing antibody to hepatitis B surface antigen. The levels of antibody were significantly higher in group 1 at each stage of the follow-up period, including a month after a booster vaccination was given. The positive response was maintained in almost all the initial responders for the 24 month duration of the study. No significant side effect was documented in any of the participants. The results suggest that population at risk in developing countries could be protected with small doses of vaccine administered intradermally.
Similar content being viewed by others
References
Prince AM (1970) Prevalence of serum hepatitis related antigen (SH) in different geographic regions. Am J Trop Med Hyg19: 872–879
Tabor S, Gerety RJ (1979) Hepatitis B virus infection in infants and toddlers in Nigeria: The need for early intervention. J Paediatr 95: 647–650
Maupas P, Goudeau A, Coursaget P, Drucker J (1976) Immunization against hepatitis B in man. Lancet i: 1367–1370
Szmuness W, Stevens CE, Marley EJ, Zank EA, Oleszko WR, Williams DC, Sadousky R, Morrison JM, Kellner A (1980) Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high risk population in the United States. N Engl J Med 202: 883–841
Nicholson KG, Prestage H, Cole PJ, Turner GS, Baver SP (1981) Multisite intradermal anti rabies vaccination. Lancet ii: 915–918
Adamowicz PH, Garfaux G, Platel A, Multer L, Vacher B, Mozert MC, Prunet P (1981) Large scale production of an hepatitis B vaccine. In:Maupas P, Guesry P (eds) Inserm symposium 18. Elsevier, North-Holland, pp 37–56
Nicholson KG, Turner GS, Aoki FY (1978) Immunisation with a human diploid cell strain of rabies virus vaccine: two year results. J Infect Dis 137: 783–788
Furlong J, Lea G (1981) Rabies prophylaxis simplified. Lancet ii: 1311
Miller KD, Gibbs RD, Mulligan MM, Nutman BT, Francis DP (1983) Intradermal hepatitis B virus vaccine. Immunogenicity and side effects in adults. Lancet ii: 1454–1456
Zoulek G, Lorbeer B, Jilg W, Dienhardt F (1984) Evaluation of reduced dose of hepatitis B vaccine administered intradermally. J Med Virol 14: 27–32
Author information
Authors and Affiliations
Additional information
With 1 Figure
Rights and permissions
About this article
Cite this article
Ayoola, E.A., Atoba, M.A. & Johnson, A.O.K. Intradermal vaccination against hepatitis B virus infection in an endemic area (Nigeria), two year results. Archives of Virology 91, 291–296 (1986). https://doi.org/10.1007/BF01314288
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01314288